Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Working conditions and non-workplace factors affect COVID-19 mortality in England

Working conditions and non-workplace factors affect COVID-19 mortality in England

B.1.1.7 not associated with change in serial interval of COVID-19

B.1.1.7 not associated with change in serial interval of COVID-19

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Virtual analysis identifies a potential natural inhibitor of SARS-CoV-2 Nsp15

Virtual analysis identifies a potential natural inhibitor of SARS-CoV-2 Nsp15

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

Study identifies mechanism behind SARS-CoV-2 fusion of host cells

Study identifies mechanism behind SARS-CoV-2 fusion of host cells

Latest round of REACT-1 finds SARS-CoV-2 prevalence has halved since previous round

Latest round of REACT-1 finds SARS-CoV-2 prevalence has halved since previous round

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.